INTRODUÇÃO: Na última década surgiu uma nova técnica, o sequenciamento de nova geração, que, contrário ao método tradicional de Sanger, permite o sequenciamento em paralelo e em larga escala de múltiplos genes, ou até mesmo todos os genes humanos, a menor custo e com uma análise mais acelerada. Essa técnica possibilitou a descoberta de novos genes responsáveis por diversas doenças mendelianas, sendo rapidamente incorporada no contexto clínico. OBJETIVOS: comparar os resultados das técnicas de Sanger e sequenciamento de nova geração em amostras controle; introduzir a técnica de sequenciamento de nova geração no contexto clínico nas casuísticas de doenças ósseas genéticas e RASopatias; avaliar a sensibilidade diagnóstica desta técnica em amostras sem dados clínicos fornecidos. MÉTODOS: o sequenciamento de nova geração (sob a forma de um painel de genes customizado ou do exoma) foi realizado em amostras com mutações identificadas previamente por Sanger e em dois grupos de doenças mendelianas, 144 pacientes com doenças ósseas e 79 com RASopatias, além de 90 amostras sem dados clínicos conhecidos (45 casos e 45 controles). A técnica de Sanger foi aplicada em 29 amostras de doenças ósseas e em 81 amostras para confirmação de variantes identificadas pelo sequenciamento de nova geração. RESULTADOS: A sensibilidade da técnica de sequenciamento de nova geração foi estimada em 95,92% e a especificidade em 98,77%. Na casuística de doenças ósseas, a sensibilidade diagnóstica das amostras sequenciadas por Sanger foi de 69% (20/29), por painel customizado, 60% (75/125) e por exoma, 63% (12/19). Na casuística de RASopatias, a sensibilidade diagnóstica através do exoma foi de 46% (36/79). Como resultado deste trabalho, dois genes novos associados a RASopatias (LZTR1 e SOS2) e um associado a uma displasia esquelética (PCYT1A) foram identificados. Na análise das amostras sem conhecimento prévio da hipótese clínica foi obtida uma sensibilidade diagnóstica de 46,67% (21/45), mas que chegou a 73,08% (14/26) para as hipóteses de erros inatos do metabolismo. CONCLUSÕES: Foi demonstrado que a sensibilidade e a especificidade da técnica do sequenciamento de nova geração são altas e correspondentes a valores encontrados por outros grupos na literatura. Essa técnica foi considerada apropriada não apenas no contexto de pesquisa, demonstrado aqui pela descoberta de três novos genes associados a doenças mendelianas, como também para análises clínicas. Neste estudo a técnica foi aplicada com sucesso no contexto clínico, seja pelo painel customizado, seja pelo exoma, com uma positividade semelhante à encontrada pela técnica de Sanger. Mesmo na análise de amostras sem história clínica prévia foi possível identificar variantes patogênicas em quase metade dos casos, e numa porcentagem ainda maior quando a doença era um erro inato do metabolismo. Essa sensibilidade é comparável à obtida pela espectroscopia de massas em Tandem aplicada à triagem de múltiplas condições simultaneamente, o que sugere que a técnica do sequenciamento de nova geração poderá ser incorporada ao programa de triagem neonatal no futuro, ampliando o emprego de testes genéticos em complementaridade aos testes bioquímicos tradicionais / INTRODUCTION: In the last decade a new technique, the next generation sequencing, has emerged, which, contrary to the traditional Sanger method, performs parallel and high-throughput sequencing of multiple genes, or even all human genes, at a lower cost and with a faster analysis. This technique allowed the discovery of new genes responsible for several Mendelian diseases and has been quickly incorporated into the clinical context. OBJECTIVES: to compare the results of Sanger technique and next generation sequencing in control samples; to apply the next generation sequencing technique in the clinical practice to the cases of genetic skeletal disorders and RASopathies; to evaluate the diagnostic yield of this technique in samples without clinical data provided. METHODS: Next generation sequencing (in the form of a customized gene panel or exome) was performed in samples with mutations previously identified by Sanger sequencing and in two groups of Mendelian diseases, 144 patients with skeletal disorders and 79 patients with RASopathies, besides 90 samples with unknown clinical data (45 cases and 45 controls). The Sanger technique was applied in 29 samples of skeletal disorders and in 81 samples for confirmation of variants identified by next generation sequencing. RESULTS: The sensitivity of the next generation sequencing technique was estimated at 95.92% and the specificity at 98.77%. In the case of skeletal disorders, the diagnostic yield of the samples sequenced by Sanger was 69% (20/29), by customized panel, 60% (75/125), and by exome, 63% (12/19). In the individuals with RASopathies, the diagnostic yield through exome sequencing was 46% (36/79). As a result of this study, two new genes associated with RASopathies (LZTR1 and SOS2) and one associated with a skeletal dysplasia (PCYT1A) were identified. In the analysis of the samples without previous knowledge of the clinical hypothesis, a total diagnostic yield of 46.67% (21/45) was obtained, but it was up to 73.08% (14/26) in the group with hypothesis of inborn errors of metabolism. CONCLUSIONS: It was demonstrated that the sensitivity and specificity of the next generation sequencing technique are high and are similar to values found by other groups in the literature. The technique was considered appropriate not only for research, as demonstrated here by the identification of three new genes associated to Mendelian diseases, but also for clinical analysis. In this study the technique was successfully applied in the clinical context, both by customized panel and by exome, with positivity similar to that obtained by the Sanger technique. Even in the analysis of samples with no previous clinical history, it was possible to identify pathogenic variants in almost half of the cases, and an even greater percentage was obtained when the disease was an inborn error of metabolism. This sensitivity is comparable to that obtained by Tandem mass spectroscopy applied to multi-condition screening, suggesting that the next generation sequencing technique may be incorporated in the future into the neonatal screening program, increasing the use of genetic testing in complementarity to the biochemical tests

INTRODUÇÃO: Na última década surgiu uma nova técnica, o sequenciamento de nova geração, que, contrário ao método tradicional de Sanger, permite o sequenciamento em paralelo e em larga escala de múltiplos genes, ou até mesmo todos os genes humanos, a menor custo e com uma análise mais acelerada. Essa técnica possibilitou a descoberta de novos genes responsáveis por diversas doenças mendelianas, sendo rapidamente incorporada no contexto clínico. OBJETIVOS: comparar os resultados das técnicas de Sanger e sequenciamento de nova geração em amostras controle; introduzir a técnica de sequenciamento de nova geração no contexto clínico nas casuísticas de doenças ósseas genéticas e RASopatias; avaliar a sensibilidade diagnóstica desta técnica em amostras sem dados clínicos fornecidos. MÉTODOS: o sequenciamento de nova geração (sob a forma de um painel de genes customizado ou do exoma) foi realizado em amostras com mutações identificadas previamente por Sanger e em dois grupos de doenças mendelianas, 144 pacientes com doenças ósseas e 79 com RASopatias, além de 90 amostras sem dados clínicos conhecidos (45 casos e 45 controles). A técnica de Sanger foi aplicada em 29 amostras de doenças ósseas e em 81 amostras para confirmação de variantes identificadas pelo sequenciamento de nova geração. RESULTADOS: A sensibilidade da técnica de sequenciamento de nova geração foi estimada em 95,92% e a especificidade em 98,77%. Na casuística de doenças ósseas, a sensibilidade diagnóstica das amostras sequenciadas por Sanger foi de 69% (20/29), por painel customizado, 60% (75/125) e por exoma, 63% (12/19). Na casuística de RASopatias, a sensibilidade diagnóstica através do exoma foi de 46% (36/79). Como resultado deste trabalho, dois genes novos associados a RASopatias (LZTR1 e SOS2) e um associado a uma displasia esquelética (PCYT1A) foram identificados. Na análise das amostras sem conhecimento prévio da hipótese clínica foi obtida uma sensibilidade diagnóstica de 46,67% (21/45), mas que chegou a 73,08% (14/26) para as hipóteses de erros inatos do metabolismo. CONCLUSÕES: Foi demonstrado que a sensibilidade e a especificidade da técnica do sequenciamento de nova geração são altas e correspondentes a valores encontrados por outros grupos na literatura. Essa técnica foi considerada apropriada não apenas no contexto de pesquisa, demonstrado aqui pela descoberta de três novos genes associados a doenças mendelianas, como também para análises clínicas. Neste estudo a técnica foi aplicada com sucesso no contexto clínico, seja pelo painel customizado, seja pelo exoma, com uma positividade semelhante à encontrada pela técnica de Sanger. Mesmo na análise de amostras sem história clínica prévia foi possível identificar variantes patogênicas em quase metade dos casos, e numa porcentagem ainda maior quando a doença era um erro inato do metabolismo. Essa sensibilidade é comparável à obtida pela espectroscopia de massas em Tandem aplicada à triagem de múltiplas condições simultaneamente, o que sugere que a técnica do sequenciamento de nova geração poderá ser incorporada ao programa de triagem neonatal no futuro, ampliando o emprego de testes genéticos em complementaridade aos testes bioquímicos tradicionais / INTRODUCTION: In the last decade a new technique, the next generation sequencing, has emerged, which, contrary to the traditional Sanger method, performs parallel and high-throughput sequencing of multiple genes, or even all human genes, at a lower cost and with a faster analysis. This technique allowed the discovery of new genes responsible for several Mendelian diseases and has been quickly incorporated into the clinical context. OBJECTIVES: to compare the results of Sanger technique and next generation sequencing in control samples; to apply the next generation sequencing technique in the clinical practice to the cases of genetic skeletal disorders and RASopathies; to evaluate the diagnostic yield of this technique in samples without clinical data provided. METHODS: Next generation sequencing (in the form of a customized gene panel or exome) was performed in samples with mutations previously identified by Sanger sequencing and in two groups of Mendelian diseases, 144 patients with skeletal disorders and 79 patients with RASopathies, besides 90 samples with unknown clinical data (45 cases and 45 controls). The Sanger technique was applied in 29 samples of skeletal disorders and in 81 samples for confirmation of variants identified by next generation sequencing. RESULTS: The sensitivity of the next generation sequencing technique was estimated at 95.92% and the specificity at 98.77%. In the case of skeletal disorders, the diagnostic yield of the samples sequenced by Sanger was 69% (20/29), by customized panel, 60% (75/125), and by exome, 63% (12/19). In the individuals with RASopathies, the diagnostic yield through exome sequencing was 46% (36/79). As a result of this study, two new genes associated with RASopathies (LZTR1 and SOS2) and one associated with a skeletal dysplasia (PCYT1A) were identified. In the analysis of the samples without previous knowledge of the clinical hypothesis, a total diagnostic yield of 46.67% (21/45) was obtained, but it was up to 73.08% (14/26) in the group with hypothesis of inborn errors of metabolism. CONCLUSIONS: It was demonstrated that the sensitivity and specificity of the next generation sequencing technique are high and are similar to values found by other groups in the literature. The technique was considered appropriate not only for research, as demonstrated here by the identification of three new genes associated to Mendelian diseases, but also for clinical analysis. In this study the technique was successfully applied in the clinical context, both by customized panel and by exome, with positivity similar to that obtained by the Sanger technique. Even in the analysis of samples with no previous clinical history, it was possible to identify pathogenic variants in almost half of the cases, and an even greater percentage was obtained when the disease was an inborn error of metabolism. This sensitivity is comparable to that obtained by Tandem mass spectroscopy applied to multi-condition screening, suggesting that the next generation sequencing technique may be incorporated in the future into the neonatal screening program, increasing the use of genetic testing in complementarity to the biochemical tests

Investigation of the relationship between iron deficiency, iron supplementation and susceptibility to infection, was suggested by the author's initial observations of an association of anaemia with serious bacterial infections in infancy in Papua New Guinea. The bulk of previous longitudinal clinical intervention studies in infancy showed beneficial effects of iron supplementation. However, defects of control and design and recording in these studies and contradictory anecdotal reports left the question unresolved. A prospective, placebo-controlled, randomised, double-blind trial of iron prophylaxis (3ml intramuscular iron dextran = 150mg Fe) to two month old infants was carried out on the North Coast of Papua New Guinea where there is high transmission of malaria. A literature review, pilot studies, protocol, demography, geography and laboratory methods developed are described. Findings indicate that the placebo control group became relatively iron deficient over the first year of life and that the iron dextran group had adequate, although not excessive iron stores and a higher mean haemoglobin; however, the prevalence and effects of malaria recorded in the field were higher in the iron dextran group. Analysis of field and hospital infectious morbidity in the trial indicated a deleterious association with iron dextran for all causes including respiratory infections (the main single reason for admission). Total duration of hospitalisation was significantly increased in the iron dextran group. Analysis of other factors showed (1) a higher admission rate associated with low weight-for-height recorded at the start of the trial; (2) a significant positive correlation between birth haemoglobin and hospital morbidity rates; (3) increased malaria rates in primiparous mothers of the cohort infants who received iron infusion during pregnancy; (4) lower relative risk of malaria associated with iron prophylaxis in individuals with alpha thalassaemia, which was found to be highly prevalent in this region. In conclusion, it is suggested that policies of iron supplementation, total dose iron injection and routine presumptive iron therapy for anaemia which are widely in practice in malaria endemic areas should be closely reviewed.

Introdução: A cardiomiopatia hipertrófica (CH) é uma doença cardíaca estrutural primária, caracterizada por hipertrofia do ventrículo esquerdo, sem dilatação, geralmente assimétrica e predominantemente septal. Na população geral a prevalência estimada da CH é de 0,2% (1:500), correspondendo a 0,5% de todas as cardiopatias. Atualmente estão descritas mais de 1400 mutações associadas à CH em 20 genes relacionados com os miofilamentos do sarcômero, o disco-Z e o transporte de cálcio, sendo que os três mais associados são os genes MYH7, MYBPC3 e TNNT2, responsáveis por 50% do casos com diagnóstico molecular positivo no Brasil. Dessa forma, o advento de novas tecnologias de sequenciamento de DNA de alta performance promete revolucionar o diagnóstico molecular, tornando mais rápida e barata a identificação de alterações genéticas, impactando positivamente na custo-efetividade do manejo diagnóstico e terapêutico de pacientes e famílias com o diagnóstico de CH. Materiais e Métodos: Noventa e uma amostras de uma casuística de pacientes não relacionados, portadores de CH com diagnóstico molecular prévio para os 3 genes mais associados (19 positivas e 72 negativas) foram utilizadas juntamente com uma amostra referência do HapMap (NA12878) na validação de um pipeline proposto para a identificação de alterações genéticas em um painel com 74 genes associados à cardiomiopatias hereditárias, utilizando a plataforma Ion Torrent PGM. A etapa de chamada de variantes foi testada em dois limiares diferentes de cobertura de sequenciamento (30x e 10x) e três limiares de frequência de alelo variante (35%, 25% e 20%). A amostra NA12878 foi utilizada na aferição de valores de reprodutibilidade intra e inter-ensaio. As amostras da casuística de CH com diagnóstico molecular prévio negativo foram utilizadas na análise de ganho diagnóstico. Eram consideradas alterações potencialmente patogênicas aquelas que apresentassem associação prévia com CH ou classificação deletéria em dois de três algoritmos de predição de impacto funcional (PROVEAN, SIFT, PolyPhen2) e MAF<0,01, se disponível. Resultados: A plataforma de sequenciamento utilizada apresentou desempenho aceitável, gerando em média 165,9 ±13,1 Mb, com um valor médio de 146,9 ± 11,54 Mb acima de PhredQ>=20, por amostra. O valor médio de cobertura de sequenciamento por amostra foi de 250 ± 23,94x, com 95,2% das regiões alvo cobertas pelo menos 10x. A sensibilidade máxima observada para SNVs foi de 96,7% enquanto que para InDels foi 28,5%. Os valores de reprodutibilidade inter e intra-ensaio de 89,5% e 87,3%, respectivamente. Das 72 amostras negativas, 35 puderam ser reclassificadas como positivas, sendo que os dois genes com mais ocorrências de alterações genéticas foram FLNC e TRIM63, ambos já relacionados com CH. Vinte e duas amostras foram reclassificadas como inconclusivas e 15 permaneceram negativas. O ganho diagnóstico foi de 21,5%. Conclusões: A plataforma Ion Torrent PGM apresenta potencial no sequenciamento de genes relacionados à cardiomiopatias hereditárias e o pipeline validado mostrou valores analíticos praticáveis em uma rotina diagnóstica. A utilização do painel genético ampliado se mostrou viável na detecção de alterações genéticas, propiciando uma boa margem de ganho diagnóstico em comparação com o sequenciamento apenas dos três genes mais associados à CH / Introduction: Hypertrophic cardiomyopathy (HCM) is a primary cardiac disease, mainly characterized by unexplained left ventricle hypertrophy, in the absence of dilatation, usually asymmetric and predominantly septal. The estimated prevalence is 1:500 individuals in the general population, corresponding for 0.5% of all cardiac diseases. Up to now, more than 1400 mutations are associated with HCM in 20 genes related with sarcomeric myofibrils, Z-disc and calcium homeostasis, wherein the 3 most associated genes are MYH7, MYBPC3 and TNNT2, accounting for 50% of cases with positive molecular diagnostics in Brazil. Thus, the advent of new high throughput DNA sequencing technologies promise to revolutionize the use of molecular diagnostics, turning the identification of genetic mutations in a fast and cheap practice, increasing the cost-effectiveness of diagnostic and treatment of patients and families with HCM. Materials and Methods: Ninety one samples from an HCM casuistic of unrelated individuals with previous molecular diagnostics for the three most HCM-associated genes (19 positives and 72 negatives) were processed along with a reference HapMap sample (NA12878) in the validation process of a pipeline proposed for the detection of genetic alterations in a genetic panel composed of 74 genes associated with inherited cardiomyopathies, using Ion Torrent PGM platform. The variant call step was tested for two cutoffs of sequencing coverage (30x and 10x) and three cutoffs of variant allele frequency (35%, 25% and 20%). The sample NA12878 was used in the assessment of intra and inter-assay reproducibility. Negative samples from the HCM casuistic were used in the assessment of diagnostic yield. Variants were considered potentially pathogenic if previously described as associated with HCM or if presenting a deleterious score in at least two of three impact prediction algorithms tested (PROVEAN, SIFT and PolyPhen-2) and MAF < 0.01, if available. Results: The chosen next-generation sequencing platform presented an acceptable performance, with a mean throughput of 165,9 ±13,1 Mb, with a mean value of 146,9 ± 11,54 Mb above PhredQ >= 20. Mean sequencing coverage was 250 ± 23,94x, wherein 95.2% of target bases were covered at least 10x. Maximum achieved sensitivity for SNVs was 96.7% while for InDels was 28.5%. Both values of inter and intra-assay reproducibility were 89.5% and 87.3%, respectively. Of all 72 negative samples, 35 were reclassified as positive with the two most frequently mutated genes being FLNC and TRIM63, both already associated with HCM. Twenty two samples were reclassified as inconclusive and 15 remained negatives. Diagnostic yield was 21.5%. Conclusions: Ion Torrent PGM platform presented a feasible potential for the sequencing of inherited cardiomyopathies-associated genes and the designed pipeline presented reliable analytical values for diagnostic use. The expanded panel proved to be a good strategy for the detection of genetic alteration providing a good value of diagnostic yield in comparison with the sequencing of the three most HCM-associated genes alone

Recent genome-wide sequencing projects revealed the pervasive transcription of intergenic long noncoding RNAs (lincRNAs) in eukaryotic genomes (reviewed in Ponting et al. 2009). For the vast majority of lincRNAs, their mechanisms of function remain largely unrecognized. However, the genome-wide signatures of functionality associated with many lincRNAs, including apparent evolutionary sequence conservation, spatial and temporal-restricted expression patterns, strong associations with epigenetic marks, and reported molecular and cellular functions, reinforce their biological relevance. My work investigates lincRNAs that post-transcriptionally regulate gene abundance by competing for the binding of common microRNAs (miRNAs) with protein-coding transcripts, termed competitive endogenous RNAs (ceRNAs) acting lincRNAs (lnceRNAs). First, I examine the biological relevance of this post-transcriptional regulation of gene abundance by ceRNAs. Next, I estimate the genome-wide prevalence of lnceRNAs in mouse embryonic stem cells (mESCs) and characterize their properties. Finally, using two specific examples of lnceRNAs, I show the contributions of lnceRNAs to human monogenic and complex trait diseases. Collectively, these results illustrate that lnceRNAs provide a novel layer of post-transcriptional regulation via a miRNA-mediated mechanism that contributes to organismal and cellular biology.

Despite a decade of publications investigating the effect of germline polymorphisms on both toxicity related to treatment with 5-fluorouracil-based (5-FU) chemotherapy and prognosis following diagnosis with colorectal cancer (CRC), few genetic biomarkers have been identified convincingly. For 5-FU toxicity and CRC prognosis, in four results chapters, this thesis aims to validate previously-reported genetic biomarkers, identify new markers, determine the mechanistic basis of associated polymorphisms, and expand upon methods in the field. The first three results chapters investigate genetic biomarkers for the prediction of toxicity caused by 5-FU-based treatment, particularly for the 5-FU prodrug capecitabine (Xeloda®, Roche). In the first, a systematic review and meta-analysis is performed for all variants that have been previously studied for an association with toxicity caused by any 5-FU-based drug regimen. 16 studies are analysed, including 36 previously-studied variants. Four variants show strong evidence of affecting a patient’s risk of global (any) 5-FU-related toxicity upon analysis of both the existing data and over 900 patients from the QUASAR2 trial of capecitabine +/- bevacizumab (Avastin®, Roche/Genentech): DPYD 2846, DPYD *2A, TYMS 5’VNTR and TYMS 3’UTR. Next, 1,456 polymorphisms in 25 genes involved in the activation, action or degradation of 5-FU are investigated in 1,046 patients from QUASAR2. At a Bonferroni-corrected p-value threshold of 3.43e-05, three novel associations with capecitabine-related toxicity are identified in DPYD (rs12132152, rs7548189, A551T) and the previously-identified TYMS 5’VNTR and 3’UTR toxicity polymorphisms are refined to a tagging SNP (rs2612091) downstream of TYMS and intronic to the adjacent ENOSF1, the latter of which appears to be functional. Finally, a genome-wide investigation of 4.77 million directly genotyped or imputed SNPs identifies one variant (rs2093152 on chr20) as significantly associated with capecitabine-related diarrhoea (p<5e-08), though no associations meet this threshold for global toxicity. In the study of CRC prognosis, a severe left truncation to the VICTOR trial is defined and shown to probably reduce statistical power but not bias effect estimates. Applying standard and novel genome-wide analysis approaches, a set of 43 SNPs are prioritised for future work. With over one million new CRC cases annually, this work helps define biomarkers that could become broadly applicable in the clinical setting.

The intimate relationship between the higher-order chromatin organisation and the regulation of gene expression is increasingly attracting attention in the scientific community. Thanks to high-resolution microscopy, genome-wide molecular biology tools (3C, ChIP-on-chip), and bioinformatics, detailed structures of chromatin loops, territories, and nuclear domains are gradually emerging. However, to fully reveal a comprehensive map of nuclear organisation, some fundamental questions remain to be answered in order to fit all the pieces of the jigsaw together. The underlying mechanisms, precisely organising the interaction of the different parts of chromatin need to be understood. Previous work in our lab hypothesised and verified the “transcription factory” model for the organisation of mammalian genomes. It is widely assumed that active polymerases track along their templates as they make RNA. However, after allowing engaged polymerases to extend their transcripts in tagged precursors (e.g., Br-U or Br-UTP), and immunolabelling the now-tagged nascent RNA, active transcription units are found to be clustered in nuclei, in small and numerous sites we call “transcription factories”. Previous work suggested the transcription machinery acts both as an enzyme as well as a molecular tie that maintains chromatin loops, and the different classes of polymerases are concentrated in their own dedicated factories. This thesis aims to further characterise transcription factories. Different genes are transcribed by different classes of RNA polymerase (i.e., I, II, or III), and the resulting transcripts are processed differently (e.g., some are capped, others spliced). Do factories specialise in transcribing particular subsets of genes? This thesis developed a method using replicating minichromosomes as probes to examine whether transcription occurs in factories, and whether factories specialise in transcribing particular sets of genes. Plasmids encoding the SV40 origin of replication are transfected into COS-7 cells, where they are assembled into minichromosomes. Using RNA fluorescence in situ hybridisation (FISH), sites where minichromosomes are transcribed are visualised as discrete foci, which specialise in transcribing different groups of genes. Polymerases I, II, and III units have their own dedicated factories, and different polymerase II promoters and the presence of an intron determine the nuclear location of transcription. Using chromosome conformation capture (3C), minichromosomes with similar promoters are found in close proximity. They are also found close to similar endogenous promoters and so are likely to share factories with them. In the second part of this thesis, I used RNA FISH to confirm results obtained by tiling microarrays. Addition of tumour necrosis factor alpha (TNF alpha) to human umbilical vein endothelial cells induces an inflammatory response and the transcription of a selected sub-set of genes. My collaborators used tiling arrays to demonstrate a wave of transcription that swept along selected long genes on stimulation. RNA FISH confirmed these results, and that long introns are co-transcriptionally spliced. Results are consistent with one polymerase being engaged on an allele at any time, and with a major checkpoint that regulates polymerase escape from the first few thousand nucleotides into the long gene.

GATA1 and KLF1 are transcription factors that regulate genes which are important for the development of erythroid cells. The GATA1 transcriptional co-factor FOG1 has been shown to be essential in a wide range of GATA1 dependent cellular functions. Here we tried to understand the diverse mechanisms by which GATA1 and KLF1 recognize their binding sites, how the GATA1 recognition mechanisms are affected by complexation with either FOG1 or KLF1 and how the GATA1 recognition mechanisms affect the transcriptional regulation of the erythroid differentiation. We profiled the DNA binding specificities/affinities of a GATA1 fragment (mGATA1NC), that contains only the two DNA binding domains (N-terminal and C-terminal Zn finger), and the DNA binding specificities/affinities of a KLF1 fragment (mKLF1257-358), that contains the three DNA binding domains, using a novel methodology that combines EMSA with high throughput sequencing (EMSA-seq (Wong et al., 2011a)). We also profiled the DNA binding specificities of the C-terminal Zn finger of GATA1 alone (mGATA1C), the wt-mGATA1, the wt-mGATA1/wt-mFOG1 complex and the mGATA1NC/mKLF1257-358 complex. At first, we confirmed that the N-terminal Zn finger of GATA1 has a strong preference for the “GATC” motif, whereas the C-terminal Zn finger of GATA1 has a strong preference for the “GATA” motif. Next, we found that in the mGATA1NC, both DNA binding domains can bind simultaneously a wide range of different positional combinations of the co-occurring “GATA” and “GATC” motifs, on the same DNA sequence. The wt-mGATA1 did not show the ability to bind in the same co-occurring motifs implying an effect of the non-DNA binding domains of the protein in the regulation of its DNA binding specificities. On the contrary, complexation of wt-mGATA1 with the wt-mFOG1 partially restored its ability to bind in a now limited range of different positional combinations of the co-occurring “GATA” and “GATC” motifs, on the same DNA sequence. Similar observations were made for other pairs of GATA1 N-terminal and C-terminal Zn finger specific motifs. We then projected the GATA1 DNA binding specificities/affinities in vivo and we classified the GATA1 ChIP-seq peaks in low, medium or high affinity based on the number of the GATA1 motifs. We noticed that high affinity GATA1 ChIP-seq peaks tend to appear in regions with low nucleosome occupancy. We also noticed that GATA1 ChIP-seq peaks in the enhancer regions are usually high affinity whereas GATA1 ChIP-seq peaks in the proximal promoter regions are usually low affinity. Additionally, we observed that high affinity GATA1 ChIP-seq peaks are usually found in regions with increased levels of H3K4me2 and are associated with a higher decrease in the H3K4me3 levels on the TSS of the nearby genes. None of these GATA1 related in vivo observations were found for the KLF1 ChIP-seq positions. These findings significantly advance our understanding of the DNA binding properties of GATA1, KLF1 and their complexes and give an insight on the importance of the GATA1 DNA binding affinities in the regulation of the erythroid transcriptional program. Overall the work establishes an experimental and analytical framework to investigate how transcriptional co-factors can change the DNA binding specificities of specific transcription factors and how integration of the transcription factor DNA binding affinities with in vivo data can give novel insights into the transcriptional regulation.

During human immunodeficiency virus 1 (HIV-1) infection, the viral population is in constant battle with the host immune system. The cytotoxic T-lymphocyte (CTL) response, a branch of the adaptive immune response, is implicated in viral control and can drive viral evolution in the infected host population. Endogenous viral peptides, or ‘epitopes’, are presented to CTLs by human leukocyte antigen (HLA) class I molecules on the surface of infected cells where they may be identified as non-self. Mutations in or proximal to a viral epitope can result in ‘escape’ from CTLs targeting that epitope. The repertoire of epitopes which may be presented is dependent upon host class I HLA types. As such, reversion may occur after transmission due to changes in viral fitness and selection in the context of a new HLA background. Thus, parameters describing the dynamics of CTL escape and reversion are key to understanding how CTL responses within individuals relate to HIV-1 sequence evolution in the infected host population. Escape and reversion can be studied directly using biological assays and longitudinal viral sequence data, or indirectly by considering viral sequences across multiple hosts. Indirect approaches include tree based methods which detect associations between host HLA and viral sequence but do not estimate rates of escape and reversion, and ordinary differential equation (ODE) models which estimate these rates but do not consider the dependency structure inherent in viral sequence data. We introduce two models which estimate escape and reversion rates whilst accounting for the shared ancestry of viral sequence data. For our first model, we lay out an integrated Bayesian approach which combines genealogical inference and an existing epidemiological model to inform escape and reversion rate estimates. Using this model, we find evidence for correlation between escape rate estimates across widely separated geographical regions. We also observe a non-linear negative correlation between in vitro replicative capacity and escape rate. Both findings suggest that epistasis does not play a strong role in the escape process. Although our first model worked well, it had some key limitations which we address in our second method. Notably, by making a series of approximations, we are able account for recombination and analyse very large datasets which would be computationally infeasible under the first model. We verify our second approach through extensive simulations, and use the method to estimate both drug and HLA associated selection along portions of the HIV-1 genome. We test the results of the model using existing knowledge, and determine a collection of putative selected sites which warrant further investigation. Finally, we find evidence to support the notion that the CTL response played a role in HIV-1 subtype diversification.

Spinal muscular atrophy (SMA) and Charcot-Marie-Tooth disease type 2D (CMT2D)/distal SMA type V (dSMAV) are two incurable neuromuscular disorders that predominantly manifest during childhood and adolescence. Both conditions are caused by mutations in widely and constitutively expressed genes that encode proteins with essential housekeeping functions, yet display specific lower motor neuron pathology. SMA results from recessive inactivating mutations in the survival motor neuron 1 (SMN1) gene, while CMT2D/dSMAV manifests due to dominant point mutations in the glycyl-tRNA synthetase (GlyRS) gene, GARS. Using a number of different model systems, ranging from Caenorhabditis elegans to the mouse, this thesis aimed to identify potential novel therapeutic compounds for SMA, and to increase our understanding of the mechanisms underlying both diseases. I characterised a novel C. elegans allele, which possesses a point mutation in the worm SMN1 orthologue, smn-1, and showed its potential for large-scale screening by highlighting 4-aminopyridine in a screen for compounds able to improve the mutant motility defect. Previously, the gene encoding three isoforms of chondrolectin (Chodl) was shown to be alternatively spliced in the spinal cord of SMA mice before disease onset. I performed functional analyses of the three isoforms in neuronal cells with experimentally reduced Smn levels, and determined that the dysregulation of Chodl likely reflects a combination of compensatory mechanism and contributor to pathology, rather than mis-splicing. Finally, working with two Gars mutant mice and a new Drosophila model, I have implicated semaphorin-plexin pathways and axonal guidance in the GlyRS toxic gain-of-function disease mechanism of CMT2D/dSMAV.